Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the clinical phase I study of oxytocin in…

Iconovo to present positive data from a feasibility study on Nanofitins in ICOone

Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin based biologic drug against…

Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD

Iconovo AB (publ), which develops complete inhalation products for a global market, and Arcede Pharma, which develops inhalation treatments for COPD and…

Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone

Iconovo announces that the clinical phase I study of oxytocin in the company's inhaler ICOone that was initiated earlier this year in Melbourne, Australia,…

Study start for Monash University with inhaled oxytocin in ICOone

PRESSRELEASE New patent for ICOone

PRESSRELEASE 230126:  The European Patent Office EPO intends to approve Iconovo's patent application for the inhaler platform ICOone® (Communication…

Iconovo’s ICOone® inhaler platform receives new patent approval in the US

Inhalation made easy with ICOone

There is a growing interest in delivering drugs by inhalation, not only medicines that treat the lungs and airways – such as those against…